Clinical Trial Update: Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) [Phase 1]

View source ↗

Summary

A Phase 1 trial of intravaginal artesunate for HPV-positive high-grade cervical intraepithelial neoplasia (CIN2/3) has completed and results were posted in 2021…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia
• Hpv Infection

Drugs mentioned

• Artesunate (artesunate)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain) | Phase 1 | Status: COMPLETED | Results posted: 2021-04-02